Chronic hepatitis C virus hepatitis and psoriasis: No longer a contraindication to interferon use in the era of biological agents?

References

• Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000;18:363–8.
   PubMed Web of Science ®Google Scholar
• Guilera M, Forns X, Torras X, Enrìquez J, Coll S, Solà R, . Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon treatment in chronic hepatitis C. J Hepatol 2000;33:135–41.
   PubMed Web of Science ®Google Scholar
• Yurci A, Guven K, Torun E, Gursoy S, Baskol M, Akgun H, . Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2007;19:811–5.
   PubMed Web of Science ®Google Scholar
• Pellicano R, Smedile A, Peyre S, Astegiano M, Saracco G, Bonardi R, . Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view. Minerva Gastroenterol Dietol 2005;51:55–61.
   PubMedGoogle Scholar
• Taylor C, Burns DA, Wiselka MJ. Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. Postgrad Med J 2000;76:365–7.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, . A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304–12.
   PubMed Web of Science ®Google Scholar
• Larrea E, Garcia N, Qian C, Civiera MP, Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996;23:210–7.
   PubMed Web of Science ®Google Scholar
• Zylbeberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, . Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1997;30:185–91.
   Web of Science ®Google Scholar
• Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63 (Suppl 2):ii18–24.
   Google Scholar
• Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, . Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005;64:1519–20.
   PubMed Web of Science ®Google Scholar
• Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, . Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008;35: 1944–9.
   PubMed Web of Science ®Google Scholar
• Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004;51:580–4.
   PubMed Web of Science ®Google Scholar
• Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004;51:800–4.
   PubMed Web of Science ®Google Scholar
• Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62: 1078–82.
   PubMed Web of Science ®Google Scholar
• Marotte H, Fontanges E, Bailly F, Zoulim F, Trepo C, Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology 2007;46:97–9.
   PubMed Web of Science ®Google Scholar
• Paradisi A, Caldarola G, Capizzi R, Siciliano M, Annichiarico E, Vecchio FM, . Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data. J Am Acad Dermatol 2010; 62:1067–9.
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor in patients with chronic hepatitis C infection: a systematic review. Rheumatology 2011;50: 1700–11.
   PubMed Web of Science ®Google Scholar
• Behnam SE, Hindiyeh R, Fife DJ, Jeffes EW 3rd, Wu JJ. Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol 2010;35:397–8.
   PubMed Web of Science ®Google Scholar
• Zein NN; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42: 315–22.
   PubMed Web of Science ®Google Scholar
• Tellez-Zenteno JF, Negrete-Pulido O, Nunez M, Estanol-Vidal B, Garcia-Ramos G. Peripheral neuropathy during a second cycle of treatment with high doses of interferon-alpha in a patient with hepatitis C, and a review of the literature. Rev Neurol 2002;35:644–6.
   PubMed Web of Science ®Google Scholar
• Yu ML, Dai CY, Huang JE, Nai JH, Lee LP, Hseih MY, . A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553–9.
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, . Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357: 124–34.
   PubMed Web of Science ®Google Scholar
• Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, . Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47:1837–45.
   PubMed Web of Science ®Google Scholar